MoonLake Immunotherapeutics held its 2025 Annual General Meeting of Shareholders on June 5, 2025. At the meeting, all director nominees, including Dr. Jorge Santos da Silva, Simon Sturge, and Dr. Andrew Phillips, were elected. Additionally, the proposal to ratify Baker Tilly US, LLP as the Independent Auditor was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-052140), on June 06, 2025, and is solely responsible for the information contained therein.